<DOC>
	<DOCNO>NCT01091636</DOCNO>
	<brief_summary>The current standard treatment ovarian cancer , tubal cancer , primary peritoneal cancer maximal cytoreductive surgery follow chemotherapy . Recent randomized trial Gynecologic Oncology Group ( GOG ) reveal survival gain intraperitoneal chemotherapy compare intravenous chemotherapy optimal cytoreduction ovarian cancer ( GOG # 104 , GOG # 114 , GOG # 172 ) . Experts attribute survival gain earlier cycle intraperitoneal chemotherapy adhesion minimal extensive cytoreductive procedure . Hyperthermia anti-cancer activity . Especially , hyperthermia promotes chemotherapy penetrate deeper cancer tissue . Therefore , combination intraperitoneal chemotherapy hyperthermia theoretically could lead high response rate well survival outcome . *HIPEC : hyperthermic intraperitoneal chemotherapy There interim analysis 50 % patient enrol . At interim analysis , statistical test perform . The nominal significance level determine later . The exact nominal significance level determine base exact number event time interim analysis . The Stopping boundary calculate use O'Brien-Fleming error spending function</brief_summary>
	<brief_title>Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer</brief_title>
	<detailed_description>If patient allocate operation remove ovarian cancer metastatic disease abdomen , trial could consider . Before operation , laboratory test result , image result , patient 's medical history , baseline quality life check review . When optimal cytoreduction ( residual tumor &lt; 1cm ) attain , HIPEC ( hyperthermic intraperitoneal chemotherapy ) could consider . For primary advanced epithelial ovarian cancer , HIPEC perform random . For recurrent ovarian cancer , HIPEC perform completion cytoreductive procedure . Usually , HIPEC take one half hour cytoreductive surgery . After cytoreductive surgery follow HIPEC , adjuvant chemotherapy add . The cycle chemotherapy determine accord patient ' clinical outcome . The laboratory test result , image result , patient 's medical history , baseline quality life check operation , chemotherapy , chemotherapy . Cytoreduction : operation remove ovarian cancer metastatic disease There interim analysis 50 % patient enrol . At interim analysis , statistical test perform . The nominal significance level determine later . The exact nominal significance level determine base exact number event time interim analysis . The Stopping boundary calculate use O'Brien-Fleming error spending function</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Fever</mesh_term>
	<criteria>1 . Disease status Primary ovarian cancer , tubal cancer , primary peritoneal cancer ( Stage III ) 2 . Residual tumor &lt; 1cm completion cytoreductive surgery 3 . Age &lt; 75 year 4 . Expected survival &gt; 3 month 5 . Performance status : ECOG 01 6 . Adequate bone marrow function Hb ≥8 g/dl ( After correction case iron deficient anemia ) WBC ≥ 3,000/mm3 , Platelet ≥ 100,000/mm3 7 . Adequate renal function Creatinine ≤ 1.5 mg/dl 8 . Adequate hepatic function Bilirubin ≤ 1.5 mg/dl AST ALT ≤ 80 IU/L 9 . Optimal cardiopulmonary function surgery 10 . Voluntary participation get write informed consent . 1 . Unresectable extraperitoneal metastasis ( brain , bone , lung parenchyme , supraclavicular lymph node ) 2 . Suboptimal debulking ( residual tumor &gt; 1cm ) 3 . Previous History malignancy ( except excision skin cancer , thyroid cancer ) 4 . Serious heart disease renal failure 5 . Serious cardiopulmonary insufficiency 6 . Uncontrolled infection 7 . Uncontrolled intercurrent disease 8 . Psychogenic disorder 9 . Patients suitable candidate legally 10 . Pregnant breastfeeding patient 11 . Patients unsuitable candidate doctor 's decision 12 . MMMT 13 . Cancer tissue confirm surgery neoadjuvant chemotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>